BCRP mRNA and FLT3‐ITD are independent poor risk factors in adult patients with acute myeloid leukemia and intermediate or normal karyotype. (17th July 2017)

• Record Type: Journal Article
• Authors: Nasiłowska‐Adamska, Barbara; Warzocha, Krzysztof; Solarska, Iwona; Borg, Katarzyna; Pieńkowska‐Grela, Barbara; Czyż, Anna
• Is Part Of: European journal of haematology. Volume 99:Number 3(2017)
• Page Start: 255
• Page End: 261
• Publication Date: 2017-07-17
• Subjects: acute myeloid leukemia -- BCRP mRNA -- FLT3‐ITD; Hematology -- Periodicals; Blood -- Diseases -- Periodicals; Blood -- Periodicals; 616.15005
• DOI: 10.1111/ejh.12913
• Languages: English
• ISSNs: 0902-4441

Abstract

Abstract: Purpose: FMS‐like tyrosine kinase 3‐internal tandem duplication ( FLT3 ‐ITD) is aberration associated with poor prognosis in AML. We have analyzed the expression of MDR‐1, MRP‐1, and BCRP mRNA in relation to FLT3 ‐ITD in 100 AML adult patients with normal and intermediate karyotype. Methods: The RQ‐PCR method was performed to assess the expression of MDR‐1, MRP‐1, and BCRP mRNA, and the results were presented as coefficients calculated using an intermediate method according to Pfaffl's rule. Results: According to univariate analysis, the following pretreatment variables negatively influenced disease‐free survival (DFS): WBC count ≥25×10 9 /L ( P =.037), MRP‐1 mRNA ≥1.6818 ( P =.028), BCRP mRNA ≥1.1892 ( P =.004), FLT3 ‐ITD ( P =.005) and overall survival (OS): WBC count ≥25×10 9 /L ( P =.031), MRP‐1 mRNA ≥1.6818 ( P =.01), BCRP mRNA ≥1.1892 ( P =.01), FLT3 ‐ITD ( P =.001). When all prognostic variables were pooled into a multivariate model, we found that WBC count ≥25×10 9 /L ( P =.026) and BCRP mRNA ≥1.1892 ( P =.011). We observed trend in negative influence of FLT3 ‐ITD on DFS ( P =.057). BCRP mRNA ≥1.1892 ( P =.035) and FLT3 ‐ITD ( P =.006) negatively, independently influenced the OS. Conclusions: The high expressions of BCRP mRNA calculated with Pfaffl's rule and FLT3 ‐ITD are independent poor risk factors in adult patients with AML and intermediate or normal karyotype.